Now In Trials

Join Our Community of Science Lovers!

This story is a supplement to the feature "Could Our Own Proteins Be Used to Help Us Fight Cancer?" which was printed in the July 2008 issue of Scientific American.

A number of drugs currently in clinical trials would fight disease by taking advantage of the diverse functions of heat shock proteins. Some seek to inhibit the proteins, others to induce them, depending on the disorder and the HSP that is being employed or targeted.

Treatment Mechanism

	Inhibitor of HSPs
(compound able to block the functioning of HSPs that would normally help a cancer cell, virus-infected cell or pathogenic bacterium to survive)

	Induction of HSPs
(heat or chemicals able to induce a patient's own HSPs to protect an organ during surgical or other treatments)

	Vaccine/Immunotherapy
(antigenic HSP-peptide complexes that are purified, then introduced into the body to stimulate an immune response to a tumor or pathogen)

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

HSP	TREATMENT (MANUFACTURER)	DISORDER
HSP90		Alvespimycin (Kosan Biosciences)	Breast cancer
	Tanespimycin (Kosan Biosciences)	Leukemia, lymphoma, solid tumors
	CNF 2024 (Biogen Idec)
	SNX-5422 mesylate (Serenex)
	AUY-922 (Novartis)	Solid tumors
	IPI-504 (Infinity Pharmaceuticals)	Melanoma, prostate cancer
	BIIB021 (Biogen Idec)	Leukemia, lymphoma, solid tumors
HSP27		OGX-427 (OncoGenex Technologies)	Solid tumors
Various		Radio-frequency therapy	Melanoma
HSP65		HspE7 (Nventa Biopharmaceuticals)	Precancerous cervical cells infected with human papillomavirus
HSP70		AG-707 (Anitgenics)	Herpes simplex type 2
	HSPPC-70/AG-858 (Antigenics)	Chronic myeloid leukemia
HSP65		HSPPC-96/vitespen* (Antigenics)	Solid tumors
*Approved for clinical use in Russia

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American